186 related articles for article (PubMed ID: 25875198)
1. Poor recognition of risk factors for hepatitis B by physicians prescribing immunosuppressive therapy: a call for universal rather than risk-based screening.
Visram A; Chan KK; McGee P; Boro J; Hicks LK; Feld JJ
PLoS One; 2015; 10(4):e0120749. PubMed ID: 25875198
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of a computer alert programme for increasing HBV screening rates before starting immunosuppressive therapy.
Köksal AS; Toka B; Eminler AT; Hacıbekiroğlu I; Sunu C; Uslan MI; Karabay O; Parlak E
Acta Gastroenterol Belg; 2019; 82(2):279-284. PubMed ID: 31314189
[TBL] [Abstract][Full Text] [Related]
3. Admissions for hepatitis B reactivation in patients receiving immunosuppressive therapy remain unchanged from 1999 to 2014.
Patel A; Yapali S; Lok AS
Hepatol Int; 2016 Jan; 10(1):139-46. PubMed ID: 26272106
[TBL] [Abstract][Full Text] [Related]
4. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
[TBL] [Abstract][Full Text] [Related]
5. Screening for hepatitis B in chemotherapy patients: survey of current oncology practices.
Tran TT; Rakoski MO; Martin P; Poordad F
Aliment Pharmacol Ther; 2010 Jan; 31(2):240-6. PubMed ID: 19814747
[TBL] [Abstract][Full Text] [Related]
6. A Danish nationwide questionnaire study of hepatitis B virus screening before immunosuppressive therapy.
Bunyoz KI; Krarup H; Weis N
Dan Med J; 2017 Mar; 64(3):. PubMed ID: 28260595
[TBL] [Abstract][Full Text] [Related]
7. [Management of the risk of hepatitis B virus reactivation in patients receiving immunosuppressive and immunomodulatory agents in internal medicine: data from the REACTI-B survey and proposal for a management algorithm].
Terrier B; Pol S; Thibault V; Gottenberg JE; Cacoub P;
Rev Med Interne; 2012 Jan; 33(1):4-12. PubMed ID: 21889826
[TBL] [Abstract][Full Text] [Related]
8. Reactivation of occult hepatitis B virus infection following cytotoxic lymphoma therapy in an anti-HBc negative patient.
Feeney SA; McCaughey C; Watt AP; Agnaf MR; McDougall N; Wend UC; Gerlich WH; Coyle PV
J Med Virol; 2013 Apr; 85(4):597-601. PubMed ID: 23359331
[TBL] [Abstract][Full Text] [Related]
9. The difficulties of managing severe hepatitis B virus reactivation.
Roche B; Samuel D
Liver Int; 2011 Jan; 31 Suppl 1():104-10. PubMed ID: 21205146
[TBL] [Abstract][Full Text] [Related]
10. Rheumatologists' awareness of hepatitis B reactivation before immunosuppressive therapy.
Toka B; Eminler AT; Gönüllü E; Tozlu M; Uslan MI; Parlak E; Karabay O; Koksal AS
Rheumatol Int; 2019 Dec; 39(12):2077-2085. PubMed ID: 31520109
[TBL] [Abstract][Full Text] [Related]
11. PREVALENCE OF OCCULT HEPATITIS B INFECTION IN IRANIAN CANCER PATIENTS BEFORE CHEMOTHERAPY TREATMENT.
Baghbanian M; Halvani M; Roghani HS; Lotfi MH; Yazdi MF; Vahedian-Ardakani HA
Arq Gastroenterol; 2016; 53(3):175-9. PubMed ID: 27438423
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and time course of hepatitis B virus infection in patients with systemic lupus erythematosus under immunosuppressive therapy.
Watanabe R; Ishii T; Nakamura K; Shirai T; Tajima Y; Fujii H; Harigae H
Mod Rheumatol; 2013 Nov; 23(6):1094-100. PubMed ID: 23180323
[TBL] [Abstract][Full Text] [Related]
13. Computerized physician order entry-based system to prevent HBV reactivation in patients treated with biologic agents: the PRESCRIB project.
Sampedro B; Hernández-López C; Ferrandiz JR; Illaro A; Fábrega E; Cuadrado A; Iruzubieta P; Menéndez S; Cabezas J; Crespo J
Hepatology; 2014 Jul; 60(1):106-13. PubMed ID: 24585503
[TBL] [Abstract][Full Text] [Related]
14. Reactivation from occult HBV carrier status is characterized by low genetic heterogeneity with the wild-type or G1896A variant prevalence.
Inuzuka T; Ueda Y; Morimura H; Fujii Y; Umeda M; Kou T; Osaki Y; Uemoto S; Chiba T; Marusawa H
J Hepatol; 2014 Sep; 61(3):492-501. PubMed ID: 24798622
[TBL] [Abstract][Full Text] [Related]
15. [Analysis of the prevalence of HBV markers relevant to the risk of reactivation of infection in patients with hematologic diseases].
Kopacz A; Bielecka A; Mikulska M; Grabarczyk P; Zwolińska P; Wojciechowska B; Łetowska M; Kisiel E; Warzocha K; Ceglarek B; Szczepanik AB; Szczepiński A; Owczarska K; Pielaciński K; Brojer E
Przegl Epidemiol; 2012; 66(1):1-5. PubMed ID: 22708290
[TBL] [Abstract][Full Text] [Related]
16. A proposal for management of rheumatic disease patients with hepatitis B virus infection receiving immunosuppressive therapy.
Harigai M; Mochida S; Mimura T; Koike T; Miyasaka N
Mod Rheumatol; 2014 Jan; 24(1):1-7. PubMed ID: 24261752
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic antiviral therapy in allogeneic hematopoietic stem cell transplantation in hepatitis B virus patients.
Liao YP; Jiang JL; Zou WY; Xu DR; Li J
World J Gastroenterol; 2015 Apr; 21(14):4284-92. PubMed ID: 25892880
[TBL] [Abstract][Full Text] [Related]
18. The yield of universal antibody to hepatitis B core antigen donor screening in the Netherlands, a hepatitis B virus low-endemic country.
van de Laar TJ; Marijt-van der Kreek T; Molenaar-de Backer MW; Hogema BM; Zaaijer HL
Transfusion; 2015 Jun; 55(6):1206-13. PubMed ID: 25494685
[TBL] [Abstract][Full Text] [Related]
19. Rheumatologists' awareness of and screening practices for hepatitis B virus infection prior to initiating immunomodulatory therapy.
Stine JG; Khokhar OS; Charalambopoulos J; Shanmugam VK; Lewis JH
Arthritis Care Res (Hoboken); 2010 May; 62(5):704-11. PubMed ID: 20461789
[TBL] [Abstract][Full Text] [Related]
20. Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer.
Borentain P; Colson P; Coso D; Bories E; Charbonnier A; Stoppa AM; Auran T; Loundou A; Motte A; Ressiot E; Norguet E; Chabannon C; Bouabdallah R; Tamalet C; Gérolami R
J Viral Hepat; 2010 Nov; 17(11):807-15. PubMed ID: 20002298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
